NDA No.	Drug	Applicant
8–102	Tace (chlorotrianisene).	Aventis Pharmaceuticals, 399 Interpace Pkwy., P.O. Box 663, Parsippany, NJ 07054.
9–925	Dyclone (dyclonine hydrochloride (HCl)) Topical Solution, 0.5% and 1%.	AstraZeneca LP, 1800 Concord Pike, P.O. Box 8355, Wilmington, DE 19803–8355.
11–444	Tace (chlorotrianisene) Capsules, 25 milligrams (mg).	Aventis Pharmaceuticals
14–322	Meprobamate Tablets, 200 mg and 400 mg.	IMPAX Laboratories, Inc., 30831 Huntwood Ave., Hayward, CA 94544.
16–235	Tace (chlorotrianisene) Capsules, 72 mg.	Aventis Pharmaceuticals
17–829	Diprosone (betamethasone dipropionate) Aerosol.	Schering Corp., 2000 Galloping Hill Rd., Kenilworth, NJ 07033.
19–188	Gastrocrom (cromolyn sodium) Capsules.	Celltech Pharmaceuticals, Inc., 755 Jefferson Rd., P.O. Box 31710, Rochester, NY 14603–1710.
19–399	Total Parenteral Nutrition Electrolytes.	Abbott Laboratories, D–389 Bldg. AP30, 200 Abbott Park Rd., Abbott Park, IL 60064–3537.
20–227	Normiflo (ardeparin sodium) Injection.	Pharmacia & Upjohn Co., 7000 Portage Rd., Kalamazoo, MI 49001–0199.
50–370	Ilotycin Gluceptate (erythromycin gluceptate).	Eli Lilly and Co., Lilly Corp. Center, Indianapolis, IN 46285.
50–579	Monocid (cefonicid sodium) Injection.	SmithKline Beecham Pharmaceuticals, One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19101–7929.
50–581	Mefoxin (cefoxitin sodium) Premixed IV Solution.	Merck & Co., Inc., P.O. Box 4, BLA-20, West Point, PA 19486.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the applications listed in the table in this document, and all amendments and supplements thereto, is hereby withdrawn, effective March 13, 2002.

Dated: January 18, 2002.

Steven K. Galson,

Deputy Director, Center for Drug Evaluation and Research.

[FR Doc. 02–3199 Filed 2–8–02; 8:45 am]

BILLING CODE 4160–02–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 02F–0042]

Ecolab, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ecolab, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of a mixture of peroxyacetic acid, octanoic acid, acetic acid, hydrogen peroxide, peroxyoctanoic acid, and 1-hydroxyethylidene-1,1-diphosphonic acid as an antimicrobial agent on meat parts, trim, and organs.

DATES: Submit written comments on the petitioner's environmental assessment by March 13, 2002.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Andrew D. Laumbach, Center for Food Safety and Applied Nutrition (HFS–215), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 202–418–3071.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 2A4731) has been filed by Ecolab, Inc., Ecolab Center, 370 Wabasha St., St. Paul, MN 55102. The petition proposes to amend the food additive regulations in Part 173 *Secondary Direct Food Additives Permitted in Food for Human Consumption* (21 CFR part 173) to provide for the safe use of a mixture of peroxyacetic acid, octanoic acid, acetic acid, hydrogen peroxide, peroxyoctanoic acid, and 1-hydroxyethylidene-1,1-diphosphonic acid as an antimicrobial agent on meat parts, trim, and organs.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations issued under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may submit to the Dockets Management Branch written comments by March 13, 2002. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.51(b).

Dated: January 22, 2002.

L. Robert Lake,

Director of Regulations and Policy, Center for Food Safety and Applied Nutrition.

[FR Doc. 02–3139 Filed 2–8–02; 8:45 am]

BILLING CODE 4160–01–S